Drug Discovery

Aveo, Novartis scrap $326m antibody licensing deal

US-based Aveo Pharmaceuticals and Swiss drugmaker Novartis have scrapped their $326m worth licensing agreement to develop and commercialize the former’s humanized inhibitory antibody AV-380 and other related antibodies.

TRIGR Therapeutics, ABL Bio collaborate on next generation therapeutic antibodies

TRIGR Therapeutics and ABL Bio have entered into a binding agreement for TRIGR to license the global commercial rights to ABL Bio’s pipeline of novel therapeutic antibodies to treat cancer.

CVC-led consortium to buy majority stake in Recordati for €3.03bn

Private equity firm CVC Capital Partners-led consortium has agreed to acquire controlling stake in Italian drugmaker, Recordati, in a deal valued at €3.03bn.

Broad, Bayer expand partnership to develop therapies for heart failure

The Broad Institute of MIT and Harvard and Bayer are launching the Precision Cardiology Laboratory (PCL), a new endeavor that will pursue scientific insights aimed at developing new therapies for heart failure.

Biogen to pay $700m to increase stake in Samsung Bioepis

Biogen has agreed to increase its stake in biopharmaceutical company Samsung Bioepis to nearly 49.9% in a deal of about $700m with its joint venture (JV) partner Samsung BioLogics.

Lumicks, AstraZeneca and University of Cambridge create new drug discovery and biology center

LUMICKS has partnered with AstraZeneca and the University of Cambridge Biochemistry Department to form the Center of Excellence for Dynamic Single-Molecule Analysis for accelerated drug discovery and biology.

AbbVie, Calibr partner to develop T-cell therapies for solid tumors

Biopharmaceutical firm AbbVie and Calibr, the drug discovery division of Scripps Research, have entered into a collaboration to develop T-cell therapies aimed mainly at cancer, including solid tumors.

The Dementia Discovery Fund raises $350m

The Dementia Discovery Fund (DDF) has announced the completion of its fundraising, with £250m ($350m at the time of completion) raised from an influential group of strategic investors committed to developing new medicines for dementia.

Erytech confirms focus of eryaspase on solid tumors and ceases development in acute lymphoblastic leukemia

Erytech Pharma has announced that it will focus its development efforts for its product candidate eryaspase on the potential treatment of selected solid tumor indications.